Neoadjuvant chemotherapy in cervix cancer

  • Peter R. Dottino
  • Rudy A. Segna
Part of the Cancer Treatment and Research book series (CTAR, volume 70)

Abstract

Despite the decrease in the incidence of cervix cancer over the last decade, 13 500 new cases and 4400 deaths were expected in the United States in 1992 [1]. Accessibility of the cervix for cytologic evaluation via the Pap smear, visual inspection by colposcopy, and histologic evaluation by biopsy have made cervical cacer a preventable and potentially curable disease. Identification and successful treatment of precursor lesions (cervical intraepithelial neoplasia) have accounted for the decreasing incidence. Cervix cancer is prevalent among women of low socioeconomic groups, high sexual promiscuity, and multiparity. It has been found to be associated with human papilloma virus infection; however, the precise role played by viral infection in cervix cancer remains to be defined. However, there is evidence accumulating linking HPV type 16, 18, 31, and 35 infections with lower-genital-tract cancers. This has led investigators to view cervical cancer as a sexually transmitted disease.

Keywords

Radium Oncol Doxorubicin Methotrexate Gallion 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Boring CC, Squires TS, Tong T (1992). Cancer Stat 42:1.Google Scholar
  2. 2.
    Chung CK, Nahhas WA, Stryker JA, et al. (1980). Analysis of factors contributing to treatment failures in Stages IB and IIA carcinoma of the cervix. Am J Obstet Gynecol 138:550.PubMedGoogle Scholar
  3. 3.
    Van Nagell J, Donaldson E, Parker J (1977). The prognostic significance of cell type and lesion size in patients with cervical cancer treated by radical surgery. Gynecol Oncol 5:142.CrossRefGoogle Scholar
  4. 4.
    Martinbeau P, Kjorstad K (1982). Iversen Stage IB carcinoma of the cervix. The Norwegian Radium Hospital. II. Results when pelvic nodes are involved. Obstet Gynecol 60:215.Google Scholar
  5. 5.
    Noguchi H, Sahiozawa I (1987). Pelvic lymph node metastasis of uterine cervical cancer. Gynecol Oncol 27:150–158.PubMedCrossRefGoogle Scholar
  6. 6.
    Pilleron JP, Durand JC, Hamelin JP (1974). Prognostic value of node metastasis in cancer of the uterine cervix. Am J Obset Gynecol 119:458–462.Google Scholar
  7. 7.
    Inover T, Okumura M (1984). Prognostic significance of parametrial extension in patients with cervical carcinoma Stage IB, IIA and IIIB. Cancer 51:1714.Google Scholar
  8. 8.
    Inoue T (1984). Prognostic significance of the depth of invasion relating to nodal metastases, parametrial extension, and cell types. A study of 628 cases with Stage IB, IIB and IIB cervical carcinoma. Cancer 54:3035–3042.PubMedCrossRefGoogle Scholar
  9. 9.
    Boyce J, Fruchter RG, Nicastri AD, Ambiavagar P, Reinis MSS, Nelson JH (1981). Gynecol Oncol 12:154–16PubMedCrossRefGoogle Scholar
  10. 10.
    Van Nagell JR Jr, Donaldson ES, Wood EG, Parker JC Jr (1978). The significance of vascular invasion and lymphocytic infiltration in invasive cervical cancer. Cancer 41:228–234.PubMedCrossRefGoogle Scholar
  11. 11.
    Roche WO, Norris HC (1975). Microinvasive carcinoma of the cervix. Cancer 36:180.PubMedCrossRefGoogle Scholar
  12. 12.
    Gallion HH, Van Nagell JR Jr, Donaldson ES, Hanson MB, Powell DE, Maruyama Y, Yoneda J (1985). Combined radiation therapy and extrafascial hysterectomy in the treatment of Stage IB barrel-shaped cervical cancer. Cancer 56:262–265.PubMedCrossRefGoogle Scholar
  13. 13.
    Kinney WK, Alvarez RD, Reid GC, Schray MF, Soong S, Morley GW, Podratz KC, Shingleton HM (1989). Value of adjuvant whole-pelvis irradiation after Wertheim hysterec-tomy for early-stage squamous carcinoma of the cervix with pelvic nodal metastasis: A matched-control study. Gynecol Oncol 34:258–262.PubMedCrossRefGoogle Scholar
  14. 14.
    Cohen CJ, Deppe G, Yuannopoulos K, Gusberg SG (1982). Chemosensitivity testing with cis-platinum(II) diammine dichloride. I. A new concept in the treatment of carcinoma of the cervix. Gynecol Oncol 13:1–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Deppe G, Cohen CJ, Yannopoulos K, Gusberg SB (1982). Chemosensitivity testing with cis-platinum(II) diammine dichloride. II. Preliminary experience in the treatment of carcinoma of the cervix. Gynecol Oncol 13:10–18.PubMedCrossRefGoogle Scholar
  16. 16.
    Lipsztein R, Kredenster D, Dottino PR, Goodman HM, Dalton JF, Bloomer WD, Cohen CJ (1988). Combined chemotherapy and radiation therapy for advanced carcinoma of the cervix. Am J Clin Oncol 29(3):348–355.Google Scholar
  17. 17.
    Dottino PR, Plaxe SC, Beddoe AM, Johnston C, Cohen CJ (1991). Induction chemotherapy followed by radical surgery in cervical cancer. Gynecol Oncol 40:7–11.PubMedCrossRefGoogle Scholar
  18. 18.
    Fletcher GH (1980). Textbook of Radiotherapy, 3rd ed. Philadelphia: Lea and Febiger, pp. 720–773.Google Scholar
  19. 19.
    Currie WC (1971). Operative treatment of carcinoma of the cervix. J Obstet Gynecol Br Commonwealth 78:385–405.CrossRefGoogle Scholar
  20. 20.
    Bonomi P, Blessing J, Stehman FB, et al. (1985). Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix. A Gynecologic Oncology Group study. J Clinical Oncol 3:1079–1085.Google Scholar
  21. 21.
    Omura GA, Velez-Garcia E, Birch R (1981). Phase II randomized study of doxorubicin, vincristine, and 5-FU versus cyclophosphamide in advanced squamous cell carcinoma of the cervix. Cancer Treat Rep 65:901–903.PubMedGoogle Scholar
  22. 22.
    Malkasian GD Jr, Decker DG, Jorgensen EO (1976). Chemotherapy of carcinoma of the cervix. Gynecol Oncol 5:109–120.CrossRefGoogle Scholar
  23. 23.
    Krakoff IH, Cvitkovic E, Currie V, et al. (1977). Clinical pharmacologic and therapeutic studies of bleomycin given by continuous infusion. Cancer 40:2027–2037.PubMedCrossRefGoogle Scholar
  24. 24.
    Hreschchyshyn M (1963). Vincristine treatment of patients with carcinoma of the uterine cervix. Proc AACR 4:29.Google Scholar
  25. 25.
    Coleman RE, Harper PG, Gallagher C, et al. (1986). A Phase II study of ifosfamide in advanced and relapsed carcinoma of the cervix. Cancer Chemother Pharmacol 18(3):280–283.PubMedCrossRefGoogle Scholar
  26. 26.
    Wallace HJ, Hreshchyshyn MM, Wilbanks GD, et al. (1978). Comparison of the therapeutic effects of adriamycin alone versus adriamycin plus vincristine versus adriamycin plus cyclophosphamide in the treatment of advanced carcinoma of the cervix. Cancer Treat Rep 62:1435–1441.PubMedGoogle Scholar
  27. 27.
    Friedlander M, Kaye SB, Sullivan A, et al. (1983). Cervical carcinoma: A drug-responsive tumor experience with combined cisplatin, vinblastine and bleomycin therapy. Gynecol Oncol 16:275–281.PubMedCrossRefGoogle Scholar
  28. 28.
    Buxton EJ, Meanwell CA, Hilton C, et al. (1989). Combination bleomycin ifosfamide and cisplatin chemotherapy in cervical cancer. J Natl Cancer Inst 81:359–361.PubMedCrossRefGoogle Scholar
  29. 29.
    Lahousen M, Packel H, Tamussino K (1987). Chemotherapy for advanced and/or recurrent cervical cancer. Arch Gynecol 240(4):247–252.PubMedCrossRefGoogle Scholar
  30. 30.
    Hoffman MA, Roberts, WS, Bryson SCP, et al. (1988). Treatment of recurrent and metastatic cervical cancer with cisplatin, doxorubicin and cyclophosphamide. Gynecol Oncol 29:32–36.PubMedCrossRefGoogle Scholar
  31. 31.
    Rotmensch J, Senekjian EK, Javaheri G, et al. (1988). Evaluation of bolus cisplatinum and continuous 5-flourouracil infusion for metastatic and recurrent squamous cell carcinoma of the cervix. Gynecol Oncol 29:76–81.PubMedCrossRefGoogle Scholar
  32. 32.
    Edmonson JH, Johnson PS, Wieand HS, et al. (1988). Phase II studies of bleomycin, cyclophosphamide, doxorubicin and cisplatin and bleomycin and cisplatin in advanced cervical carcinoma. Am J Clin Oncol(CCT) 11(2):149–151.CrossRefGoogle Scholar
  33. 33.
    Kim DS, Moon Y, Kim KT, Whwang YY, Cho SH, Kim SR (1989). Two-year survival: Preoperative adjuvant chemotherapy in the treatment of cervical cancer Stages IB and II with bulky tumor. Gynecol Oncol 33:225–230.PubMedCrossRefGoogle Scholar
  34. 34.
    Panici PB, Scambia G, Baiocchi G, Greggi S, Ragusa G, Gallo A, Conte M, Battaglia F, Laurelli G, Rabitti C, Capelli A, Mancuso S (1991). Neoadjuvant chemotherapy and radical surgery in locally advanced cervical cancer. Cancer 67:372–379.PubMedCrossRefGoogle Scholar
  35. 35.
    Deppe G, Malviya VK, Han I, Christensen CW, Malone JM Jr, Kim Y, Ahmad K (1991). A preliminary report of combination chemotherapy with cisplatin and mitomycin-C followed by radical hysterectomy or radiation therapy in patients with locally advanced cervical cancer. Gynecol Oncol 42:178–181.PubMedCrossRefGoogle Scholar
  36. 36.
    Sardi JE, Guillermo R, Paola D, Cachau A, Ortiz OC, Sananes C, Giaroli A, Martins D, Peluffo M (1986). A possible new trend in the management of the carcinoma of the cervix uteri. Gynecol Oncol 25:139–149.PubMedCrossRefGoogle Scholar
  37. 37.
    Friedlander ML, Atkinson K, Coppleson JVM, Elliot P, Green D, Houghton R, Solomon JJ, Russell P, Tattersall MHN (1984). The integration of chemotherapy into the management of locally advanced cervical cancer: A pilot study. Gynecol Oncol 19:1–7.PubMedCrossRefGoogle Scholar
  38. 38.
    Weiner SA, Aristizabal S, Alberts DS, Surwit EA, Deatherage-Deuser K (1988). A Phase II trial of mitomycin, vincristine, bleomycin, and cisplatin (MOBP) as neoadjuvant therapy in high-risk cervical carcinoma. Gynecol Oncol 30:1–6.PubMedCrossRefGoogle Scholar
  39. 39.
    Giannone L, Brenner DE, Jones HW III, Greco FA, Burnett LS (1987). Combination chemotherapy for patients with advanced carcinoma of the cervix: Trial of mitomycin-C, vincristine, bleomycin, and cisplatin. Gynecol Oncol 26:178–182.PubMedCrossRefGoogle Scholar
  40. 40.
    Souhami L, Gil RA, Allan SE, Canary PCV, Araujo A (1991). Randomized trial of chemotherapy followed by pelvic radiation therapy in Stage IIIB carcinoma of the cervix. J Clin Oncol 9:970–977.PubMedGoogle Scholar
  41. 41.
    Tobias J, Buxton EJ, Blackledge G, Mould JJ, Monaghan J, Spooner D, Chetyawardana A (1990). Neoadjuvant bleomycin, ifosfamide and cisplatin in cervical cancer. Cancer Chemother Pharmocol 26:S59–S62.CrossRefGoogle Scholar
  42. 42.
    Goldhirsch A, Greiner R, Bleher A, Jeshko M, Dreher E, Krauer F, Cavalli F (1986). Combination of chemotherapy with methotrexate, bleomycin, and cis-platin, and radiation therapy for locally advanced carcinoma of the cervix. Am J Clin Oncol 9:12–14.PubMedCrossRefGoogle Scholar
  43. 43.
    Muss HB, Jobson VAW, Homesley HD, Welander C, Ferree C (1987). Neoadjuvant therapy for advanced squamous cell carcinoma of the cervix: Cisplatin followed by radiation therapy — A pilot study of the Gyncologic Oncology Group. Gynecol Oncol 26:35–40.PubMedCrossRefGoogle Scholar
  44. 44.
    Park TK, Choi DH, Kim SN, Lee CH, Kim YT, Kim GE, Suh CO, Lo JK (1991). Role of induction chemotherapy in invasive cervical cancer. Gynecol Oncol 41:107–112.PubMedCrossRefGoogle Scholar
  45. 45.
    Symonds RE, Burnett RA, Habeshaw T, Kaye SB, Snee MP, Watson ER (1989). The prognostic value of a response to chemotherapy given before radiotherapy in advanced cancer of cervix. Br J Cancer 59(3):473–475.PubMedCrossRefGoogle Scholar
  46. 46.
    Lara PC, Garcia-Puche JL, Pedraza V (1990). Cisplatin-ifosfamide as neoadjuvant chemotherapy in Stage IIIB cervical uterine squamous-cell carcinoma. Cancer Chemother Pharmocol 26:S36–S38.CrossRefGoogle Scholar
  47. 47.
    Nguyen PD, John B, Munoz AAK, Yazzigi R, Graham M, Franklin P (1991). Mitomycin-C/5-FU and radiation therapy for locally advanced uterine cervical cancer. Gynecol Oncol 43:220–225.PubMedCrossRefGoogle Scholar
  48. 48.
    Patton T Jr, Kavanagh JJ, Delclos L, Wallace S, Haynie TP, Gerenshen DM, Wharton JT, Bass S (1991). Five-year survival in patients given intra-arterial chemotherapy prior to radiotherapy for advanced squamous carcinoma of the cervix and vagina. Gynecol Oncol 42:54–59.PubMedCrossRefGoogle Scholar
  49. 49.
    Kuhnle H, Meerpohl HG, Eiermann W, Roben S, Lenaz L, Achterrath W (1990). Phase II study of carboplatin/ifosfamide in untreated advanced cervical cancer. Cancer Chemother Pharmacol 26:S33–S35.PubMedCrossRefGoogle Scholar
  50. 50.
    Kirsen F, Atkinson KH, Coppleson JVM, Elliott PM, Green D, Houghton R, Murray JC, Russell P, Solomon HJ, Friedlander M, Swanson CE, Tattersall MGN (1987). Combination chemotherapy followed by surgery or radiotherapy in patients with locally advanced cervical cancer. Br J Obstet Gynecol 94:583–588.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1994

Authors and Affiliations

  • Peter R. Dottino
  • Rudy A. Segna

There are no affiliations available

Personalised recommendations